Peptide library / Digestive & weight / Apraglutide
Apraglutide
An investigational weekly GLP-2 analog for short bowel syndrome with intestinal failure.
Effects studied or claimed
What it is used or promoted for, and where each effect has actually been seen
- Reduce parenteral nutrition dependence in short bowel syndromeLarge trials
How it is thought to work
Apraglutide is designed to bind the GLP-2 receptor for longer than teduglutide, enabling weekly dosing.
What the evidence shows
A phase 3 trial reported benefit in a subset of patients, and regulators have asked for further data.
Safety and unknowns
Gastrointestinal and injection site effects were commonly reported.
Regulatory status
Not approved. An additional trial has been requested by regulators.
Regulatory status changes quickly. This entry was last reviewed on 27 October 2026. Confirm current status with the FDA before relying on it.
More in Digestive & weight
BPC-157
Wellness and performanceA 15 amino acid gut-protein fragment studied almost entirely in animals, with growing interest in compounding.
Cagrilintide
In clinical trialsAn investigational long-acting amylin analog from Novo Nordisk, tested alone and combined with semaglutide.
AOD-9604
Wellness and performanceA modified fragment of human growth hormone promoted for fat loss that did not work in large trials.
General information, not medical advice. Do not buy or inject unregulated peptides.